BACKGROUND: The authors determined the incidence of acute and delayed chemotherapy-induced nausea and emesis (vomiting) (CINV) among patients receiving highly (HEC) or moderately (MEC) emetogenic chemotherapy. They also assessed whether physicians and nurses accurately recognized the incidence of acute and delayed CINV in their own practices. METHODS: A prospective, observational study of adult patients receiving HEC or MEC for the first time was performed. Before patient enrollment, medical oncologists and oncology nurses estimated the incidence of acute (Day 1) and delayed (Days 2-5) CINV after first administration of HEC and MEC in their own practices. Eligible patients from their practices then completed a 6-day diary including emetic episodes, nausea assessment, and antiemetic medication use. Observed incidence rates of acute and delayed CINV were compared with physician/nurse predictions. RESULTS: Twenty-four physicians and nurses and 298 eligible patients (67 receiving HEC and 231 receiving MEC) were recruited from 14 oncology practices in 6 countries. Greater than 35% of patients overall experienced acute nausea, whereas 13% experienced acute emesis. Delayed nausea and emesis were observed in 60% and 50% of HEC patients, respectively, and in 52% and 28% of MEC patients, respectively. Delayed symptoms appeared without acute symptoms after HEC (emesis, 38%; nausea, 33%) and MEC (emesis, 19%; nausea, 21%). Physicians and nurses accurately predicted the incidence of acute CINV but underestimated the incidence of delayed nausea and emesis after HEC by 21 and 28 percentage points, respectively, and delayed nausea after MEC by 28 percentage points. Greater than 75% of physicians and nurses underestimated the incidence of delayed CINV after both HEC and MEC. CONCLUSIONS: Physicians and nurses markedly underestimated the incidence of delayed nausea and emesis after both HEC and MEC. Delayed nausea and emesis, which may appear even in the absence of acute nausea and emesis, remain important targets for improved therapeutic intervention. Copyright 2004 American Cancer Society.
BACKGROUND: The authors determined the incidence of acute and delayed chemotherapy-induced nausea and emesis (vomiting) (CINV) among patients receiving highly (HEC) or moderately (MEC) emetogenic chemotherapy. They also assessed whether physicians and nurses accurately recognized the incidence of acute and delayed CINV in their own practices. METHODS: A prospective, observational study of adult patients receiving HEC or MEC for the first time was performed. Before patient enrollment, medical oncologists and oncology nurses estimated the incidence of acute (Day 1) and delayed (Days 2-5) CINV after first administration of HEC and MEC in their own practices. Eligible patients from their practices then completed a 6-day diary including emetic episodes, nausea assessment, and antiemetic medication use. Observed incidence rates of acute and delayed CINV were compared with physician/nurse predictions. RESULTS: Twenty-four physicians and nurses and 298 eligible patients (67 receiving HEC and 231 receiving MEC) were recruited from 14 oncology practices in 6 countries. Greater than 35% of patients overall experienced acute nausea, whereas 13% experienced acute emesis. Delayed nausea and emesis were observed in 60% and 50% of HEC patients, respectively, and in 52% and 28% of MECpatients, respectively. Delayed symptoms appeared without acute symptoms after HEC (emesis, 38%; nausea, 33%) and MEC (emesis, 19%; nausea, 21%). Physicians and nurses accurately predicted the incidence of acute CINV but underestimated the incidence of delayed nausea and emesis after HEC by 21 and 28 percentage points, respectively, and delayed nausea after MEC by 28 percentage points. Greater than 75% of physicians and nurses underestimated the incidence of delayed CINV after both HEC and MEC. CONCLUSIONS: Physicians and nurses markedly underestimated the incidence of delayed nausea and emesis after both HEC and MEC. Delayed nausea and emesis, which may appear even in the absence of acute nausea and emesis, remain important targets for improved therapeutic intervention. Copyright 2004 American Cancer Society.
Authors: Carmen L Watkins; Carlos Fernandez-Robles; Kathleen M Miller; Alexander Pine; Theodore A Stern Journal: Prim Care Companion CNS Disord Date: 2011
Authors: Juan Bayo; Paula J Fonseca; Susana Hernando; S Servitja; A Calvo; S Falagan; Estefanía García; Iria González; María José de Miguel; Quionia Pérez; Ana Milena; Antonio Ruiz; Agustí Barnadas Journal: Clin Transl Oncol Date: 2012-06 Impact factor: 3.405
Authors: Gary R Morrow; Lee Schwartzberg; Sally Y Barbour; Gianluca Ballinari; Michael D Thorn; David Cox Journal: J Community Support Oncol Date: 2014-07
Authors: Enzo Ballatori; Fausto Roila; Benedetta Ruggeri; Maura Betti; Samanta Sarti; Giancarla Soru; Giorgio Cruciani; Massimo Di Maio; Biffi Andrea; Robert R Deuson Journal: Support Care Cancer Date: 2006-08-29 Impact factor: 3.603
Authors: Steven M Grunberg; David Osoba; Paul J Hesketh; Richard J Gralla; Sussanne Borjeson; Bernardo L Rapoport; Andreas du Bois; Maurizio Tonato Journal: Support Care Cancer Date: 2004-12-14 Impact factor: 3.603
Authors: Steven M Grunberg; David Warr; Richard J Gralla; Bernardo L Rapoport; Paul J Hesketh; Karin Jordan; Birgitte T Espersen Journal: Support Care Cancer Date: 2010-10-24 Impact factor: 3.603